OXB Completes Full Ownership of US Subsidiary for Growth

OXB Achieves Complete Ownership of its US Subsidiary

OXB has successfully acquired the remaining 10% stake in its US subsidiary, solidifying its ownership of OXB US LLC. This strategic move underlines OXB's commitment to growth in the viral vector manufacturing sector, crucial for the evolving landscape of cell and gene therapies.

Strategic Move in Viral Vector Manufacturing

Acquiring full ownership of the US subsidiary aligns perfectly with OXB's global strategy. By integrating the subsidiary into its operations, OXB is poised to meet the increasing demand for high-quality vector manufacturing. This is essential for the expanding market of cell and gene therapy, which relies heavily on effective viral vectors.

Overview of OXB US LLC

Founded in Bedford, MA, OXB US LLC began its journey in 2022 as a dedicated facility for AAV manufacturing and innovation. The site has been fully absorbed into OXB's global network and successfully completed the transfer of its lentiviral platform within a short span of time.

Expanding Capabilities and Facilities

Spanning 96,000 square feet, the facility is enabled with advanced capabilities for both lentiviral and AAV vector production. This expansion has allowed OXB to onboard a variety of new programs, further enhancing its role in the global cell and gene therapy landscape.

Leadership Insights on the Acquisition

Dr. Frank Mathias, Chief Executive Officer of OXB, expressed enthusiasm over the acquisition. He emphasized that the complete ownership marks a pivotal moment for the company, reinforcing their presence within a key market.

Meeting the Demands of the Market

According to Dr. Mathias, the acquisition does not merely represent ownership; it enhances service offerings and access to advanced expertise across AAV and lentiviral-based therapies. OXB is committed to supporting clients globally, guiding them from early development to commercialization of their therapies.

About OXB and its Mission

OXB is a trailblazer in the field of cell and gene therapy. With over three decades of experience, it has established itself as a leader in viral vector development and manufacturing. Collaborating with various pharmaceutical and biotechnology innovators, OXB offers solutions across different viral vector types.

Innovative Technology and Expertise

The company boasts an impressive array of technologies for viral vector manufacturing, including the TetraVecta™ fourth-generation lentiviral vector system and optimized AAV production processes. These advancements are crucial for both clinical and commercial applications, fueling the success of therapies worldwide.

Contact OXB for More Information

For further inquiries concerning OXB, you can reach out to:

OXB Media Relations:

Sophia Bolhassan, Head of Investor Relations
T: +44 (0) 1865 509 737
E: ir@oxb.com

Frequently Asked Questions

What does the acquisition of OXB US LLC mean for OXB?

This acquisition allows OXB to strengthen its position in the viral vector manufacturing market, enhancing its capabilities in providing services to clients globally.

How will this acquisition impact OXB's growth strategy?

By achieving full ownership, OXB can better align its resources and capabilities with the growing demand for cell and gene therapy solutions.

Can you elaborate on OXB's existing facilities?

OXB maintains facilities in the UK, France, and the US, providing comprehensive global solutions in viral vector manufacturing.

What types of therapies does OXB specialize in?

OXB focuses on lentivirus and AAV-based therapies, offering a range of innovative manufacturing technologies to support various applications.

How can clients learn more about OXB's services?

Clients may visit OXB's official website or contact their investor relations team for detailed information on their offerings and capabilities.

About The Author

Even at just 28 years old, Lucas Young has made a name for himself as a writer and financial expert. Lucas is a gifted communicator of difficult financial ideas and has written a number of well-received books and articles that appeal to both new and experienced investors. The financial world has come to rely on his perceptive analysis and useful counsel. Many people have been enabled to make wise investment decisions by Lucas's commitment to financial literacy and his ability to demystify the complexities of the market. Lucas is still dedicated to advising and teaching people on their financial journeys as he shares his knowledge.

Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.